LiT4Q™
TLR4 in a Liposome
Liposomes consist of vesicles formed by the assembly of phospholipid bilayers. These vesicles can be made at ~100 nm diameters and have good stability. Liposomes are versatile and biocompatible vehicles for adjuvant formulation. As an amphiphilic molecule, the TLR4 agonist will be localized within the lipid bilayer. Furthermore, aqueous adjuvants such as QS21 can be encapsulated in the aqueous interior of the liposomes or solubilized in the aqueous bulk phase forming an adjuvant like the established adjuvant AS01B which has demonstrated good results in malaria, shingles, and TB.
Sold in a vial of 0.5 mL.
Research-grade only. Inquire about cGMP.
$325.00
Initial Details
Adjuvant Name: LiT4
Chemical Nature: Combination of adjuvant-QS21 limosome with TLR4
Primary Receptor: TLR
Secondary Receptor: TLR4
Mechanism of Action: TLR4 agonist plus potential inflammasome
Immune Profile Induced: Mixed Th1/Th2
Drug Master File: No
NIAID Support: No
Stability Information: At least 2 years at 2-8 degrees C
Storage Information 2-8 degrees C
In Vivo Use (Preclinical)
Is there an associated publication? No
Disease Area/Pathogen: Virus
Parent Organism: Severe acute respiratory syndrome-related coronavirus
Antigen: Recombinant protein
Immunization Route: IM
Readout: Immunogenicity (serology)
Host Species: Mouse-C57BL/6
Were PK/Toxicology studies conducted? No
Product Grade and Formulation(s)
Product Grade: Research-grade only
Formulation(s): Bedside mixing
Bedside mixing with antigen possible? Yes
Also used in combination adjuvant-formulation? No
Clinical
Not evaluated in humans yet
LiT4™ is a TLR4 agonist and the saponin QS21 in a liposomal formulation of about 100 nm in average diameter. The combination of TLR4 agonist and QS21 synergizes in producing a potent, balanced immune response with a T<sub>H</sub>1 bias. Each 0.5 mL vial contains 5o µg TLR agonist and 125 µg QS21.
Recently Viewed Items
You haven't viewed at any of the products yet.